Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Order results by:     
Issue Title
Vol 15, No 2 (2012) Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
Abstract PDF
(Rus)
similar documents
Vol 13, No 2 (2010) Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
Abstract PDF
(Rus)
similar documents
Ametov A.S., Karpova E.V.
"... , such as the use of incretins. Inhibitors of dipeptylpeptidase-4 (DPP-4) including Galvus (vildagliptin ..."
Vol 14, No 3 (2011) Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
Abstract PDF
(Rus)
similar documents
Ametov A.S., Karpova E.V.
"... . For one of the most efficient is the combination of metforminand DPP-4 inhibitor ..."
Vol 17, No 1 (2014) Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
Abstract PDF
(Rus)
similar documents
Biryukova E.V.
"... The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 ..."
Vol 13, No 3 (2010) Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
Abstract PDF
(Rus)
similar documents
Shestakova M.V.
"... and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian ..."
Vol 13, No 3 (2010) Vildagliptin: the first innovative DDP-4 inhibitor
Abstract PDF
(Rus)
similar documents
Villkhauer E.
"... of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor ..."
Vol 15, No 4 (2012) Russian Association of Endocrinologists reports commencement of Trajenta clinical use
Abstract PDF
(Rus)
similar documents
Vol 13, No 4 (2010) The new drug saxagliptin is now registrated in Russia
Abstract PDF
(Rus)
similar documents
Vol 17, No 4 (2014) Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
Abstract PDF
(Rus)
PDF
(Eng)
similar documents
Nedosugova L.V., Petunina N.A., Galstyan K.O.
"... with a fundamentally new mechanism of action: inhibitors of dipeptidyl peptidase-4 (DPP-4i). However, the wide ..."
Vol 19, No 3 (2016) Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
Abstract PDF
(Rus)
similar documents
Galstyan G.R., Gilyarov M.Y.
"... inhibitors (I-DPP4) compared with placebo. Until recently, HF was not considered to be a vascular or chronic ..."
Vol 21, No 5 (2018) Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
Abstract PDF
(Rus)
similar documents
Mosikian A.A., Babenko A.Y., Sevastyanova Y.A., Drai R.V., Shlyakhto E.V.
"... data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published ..."
Vol 13, No 3 (2010) Vildagliptin and its role in the treatment of diabetes mellitus
Abstract PDF
(Rus)
similar documents
Khalimov Y.S.
"... to stimulate insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of hypoglycemic agents ..."
Vol 15, No 1 (2012) Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
Abstract PDF
(Rus)
similar documents
Suntsov Y.I.
"... absolute and comparative data on use of insulin analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors ..."
Vol 15, No 3 (2012) Expert committee on introduction of incretin-based therapy in Russia: advance and failure
Abstract PDF
(Rus)
similar documents
Vol 14, No 4 (2011) Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
Abstract PDF
(Rus)
similar documents
Shestakova M.V.
"... -4 inhibitors,as well as their combination, were most common choices for initiation of treatment ..."
Vol 19, No 1 (2016) First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
Abstract PDF
(Rus)
similar documents
Galstyan K.O., Nedosugova L.V., Petunina N.A., Trakhtenberg J.A., Vostokova N.V., Karavaeva O.V., Chasovskaya T.E.
"... . To study the efficacy and safety of a new DPP-4 inhibitor (gosogliptin) in comparison ..."
Vol 17, No 4 (2014) Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
Abstract PDF
(Rus)
similar documents
Babenko A., Krasilnikova E.I., Likhonosov N.P., Likhonosova A.P., Grineva E.N.
"... and dipeptidyl peptidase (DPP)-4 inhibitors. A glucose-dependent mechanism suggests that these groups ..."
Vol 20, No 5 (2017) Second line therapy in type 2 diabetes: legacy effect activation
Abstract PDF
(Rus)
similar documents
Shestakova E.A.
Vol 21, No 5 (2018) Heart failure in diabetes: From an increased risk to a treatment target
Abstract PDF
(Rus)
PDF
(Eng)
similar documents
Standl E.
"... peptidase-4 (DPP-4) inhibitors (SAVOR-TIMI53, TECOS and EXAMINE) met the safety primary endpoint [3-point ..."
Vol 21, No 5 (2018) Role of incretin based therapies in the treatment of diabetic kidney disease
Abstract PDF
(Rus)
PDF
(Eng)
similar documents
Fioretto P., Frascati A.
"... (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used glucose lowering agents ..."
Vol 19, No 3 (2016) Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
Abstract PDF
(Rus)
similar documents
Kakorin S.V., Iskandaryan R.A., Mkrtumyan A.M.
"... is ineffective, DPP-4 inhibitors should be prescribed and renal function should be monitored. Metformin is contra ..."
Vol 15, No 4 (2012) New prospects in the treatment of diabetes mellitus
Abstract PDF
(Rus)
similar documents
Shamkhalova M.S., Trubitsyna N.P., Shestakova M.V.
"... classes of drugs: GLP-1 mimetics and DPP-4 inhibitors. Both are regarded nowadays for a number ..."
Vol 14, No 4 (2011) ACE inhibitors as a risk factor for hypoglycemia
Abstract PDF
(Rus)
similar documents
Aleksandrov A.A., Kukharenko S.S., Kulieva M.N., Shatskaya O.M., Shatskaya O.A., Mart'yanova I.I., Drozdova E.N., Kudryashova A.L.
"... including death. ACE-inhibitors, when taken withantidiabetic drugs, can cause hypoglycemic episodes ..."
Vol 15, No 4 (2012) Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascular complications
Abstract PDF
(Rus)
similar documents
Konenkov V.I., Klimontov V.V.
"... trials have shown efficacy of angiogenesis inhibitors (the ?anti-VEGF? agents) for management of diabetic ..."
Vol 12, No 1 (2009) Use of dual action inhibitor (duloxetine) in diabetic neuropathy
Abstract PDF
(Rus)
similar documents
Gur'eva I.V.
Vol 12, No 4 (2009) Control of type 2 diabetes mellitus: problems and prospects for their solution
Abstract PDF
(Rus)
similar documents
Romantsova T.I., Glinkina I.V.
"... parameters (HbA1c and fasting glycemia). Dipeptidyl peptidase-IV (DPP-IV) inhibitors are a new class ..."
Vol 19, No 1 (2016) Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
Abstract PDF
(Rus)
similar documents
Sukhareva O.Y., Shestakova M.V.
"... with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients ..."
Vol 20, No 1 (2017) Empagliflozin: a new strategy for nephroprotection in diabetes
Abstract PDF
(Rus)
similar documents
Korbut A.I., Klimontov V.V.
"... Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class ..."
Vol 14, No 2 (2011) Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
Abstract PDF
(Rus)
similar documents
Trunina E.N., Petunina N.A., Chorbinskaya S.A.
"... in the short run. The discovery and use of new hypoglycemic agents, e.g. DPP-4 inhibitors, openup opportunities ..."
Vol 14, No 4 (2011) Role of plasminogen activator inhibitor and free fatty acids in diagnosis of insulin resistance in patients with myocardial infarction
Abstract PDF
(Rus)
similar documents
Gruzdeva O.V., Barbarash O.L., Akbasheva O.E., Fedorova T.S., Palicheva E.I., Kashtalap V., Dyleva Y.A., Silonova A.A., Sionina E.V., Uchasova E.G.
"... of free fattyacids, glucose, C-peptide, insulin in serum and plasminogen activator inhibitor in blood ..."
Vol 18, No 4 (2015) Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
Abstract PDF
(Rus)
similar documents
Galstyan G.R., Sergeeva S.V.
"... The evidence for DPP-4 inhibitors effectiveness at the late stages of type 2 diabetes mellitus (T2 ..."
Vol 22, No 1 (2019) Diabetes mellitus associated with the mutation of the ABCC8 gene (MODY 12): features of clinical course and therapy
Abstract PDF
(Rus)
PDF
(Rus)
similar documents
Ovsyannikova A.K., Rymar O.D., Shakhtshneider E.V., Klimontov V.V., Koroleva E.A., Voevoda M.I.
"... resulted in extreme glycaemic excursions. Thereby, sodium–glucose cotranporter-2 (SGLT2) inhibitor ..."
Vol 16, No 2 (2013) Conservative treatment for acute coronary syndrome in patients with type 2 diabetes mellitus
Abstract PDF
(Rus)
similar documents
Kakorin S.V., Kruglyi L.B., Mkrtumyan A.M.
Vol 17, No 2 (2014) Erectile dysfunction as a manifestation of urogenital autonomic neuropathy in patients with type 1 diabetes: epidemiology, classification, pathophysiology, diagnosis and treatment options
Abstract PDF
(Rus)
PDF
(Eng)
similar documents
Galstyan G.R., Shwarts Y.G., Dubsky S.A., Lepetukhin A.E., Rozhivanov R.V., Kurbatov D.G.
Vol 19, No 6 (2016) Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
Abstract PDF
(Rus)
similar documents
Petunina N.A., Terekhova A.L., Goncharova E.V.
Vol 21, No 5 (2018) Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
Abstract PDF
(Rus)
PDF
(Eng)
similar documents
Avogaro A.
"... End-stage kidney disease DPP-4 inhibitors Lean/Overweight patients ..."
1 - 36 of 36 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)